Double-stranded oligonucleotides inhibiting C3 gene expression, conjugates and uses thereof

CN121844047APending Publication Date: 2026-04-10RIGERNA THERAPEUTICS (SUZHOU) CO LTD
-1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-09-01
Publication Date
2026-04-10

Smart Images

  • Figure 00000170_0000
    Figure 00000170_0000
  • Figure 00000170_0001
    Figure 00000170_0001
  • Figure 00000171_0000
    Figure 00000171_0000
Patent Text Reader

Abstract

Relates to the field of medicines, in particular to a double-stranded oligonucleotide for inhibiting C3 gene expression, a conjugate and application thereof. The double-stranded oligonucleotide or the conjugate thereof can obviously inhibit the expression of C3 mRNA in HepG2 cells; c3 mRNA expression in an animal body can be obviously inhibited; the C3 protein level in cynomolgus monkey serum can be obviously reduced, and the inhibition effect can last to the 42nd day; the complement substitution pathway of cynomolgus monkey serum can be obviously inhibited, but the classical pathway of serum complement is not influenced; c3 mRNA (messenger ribonucleic acid) and protein level of a CFA-IgA mouse can be reduced; c3 deposition in the kidney tissue can be reduced, and the disease course of a patient with C3 deposition in the kidney tissue can be improved; and animal hematology and blood biochemistry are not obviously abnormal. The double-stranded oligonucleotides or conjugates thereof contribute to the alleviation, prevention and / or treatment of diseases or conditions mediated by the C3 gene.
Need to check novelty before this filing date? Find Prior Art